Pierre Painsec

BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers

Florence Coussy, Rania El Botty, Sophie Château‐Joubert et al. · Science Translational Medicine · 2020 · 148 citations · Full text

Medicine, Cancer Biology, Oncology +13

PLK1 inhibition exhibits strong anti-tumoral activity in CCND1-driven breast cancer metastases with acquired palbociclib resistance

Élodie Montaudon, Joanna Nikitorowicz-Buniak, Laura Sourd et al. · Nature Communications · 2020 · 124 citations · Full text

Medicine, Oncology, Pharmacology +17

Oxidative phosphorylation is a metabolic vulnerability of endocrine therapy and palbociclib resistant metastatic breast cancers

Rania El Botty, Ludivine Morriset, Élodie Montaudon et al. · Nature Communications · 2023 · 101 citations · Full text

Medicine, Oncology, Pharmacology +17

A large collection of integrated genomically characterized patient‐derived xenografts highlighting the heterogeneity of triple‐negative breast cancer

Florence Coussy, Leanne de Koning, Marion Lavigne et al. · International Journal of Cancer · 2019 · 57 citations · Full text

Medicine, Molecular Genetics, Oncology +14

Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts

Florence Coussy, Marion Lavigne, Leanne de Koning et al. · Theranostics · 2020 · 56 citations · Full text

Medicine, Oncology, Pharmacology +15